Global Information
회사소개 | 문의 | 비교리스트

육종 치료제 시장 규모, 점유율, 동향 분석 : 치료 유형별(화학요법, 표적요법), 주요 시장별(미국, 영국, 독일, 스페인, 이탈리아, 프랑스, 일본), 부문 예측(2018-2023년)

Sarcoma Drugs Market Size, Share & Trends Analysis Report By Treatment Type (Chemotherapy, Targeted Therapy), By Major Markets (U.S., U.K., Germany, Spain, Italy, France, Japan), And Segment Forecasts, 2018 - 2023

리서치사 Grand View Research, Inc.
발행일 2018년 07월 상품 코드 682157
페이지 정보 영문 93 Pages
가격
US $ 5,950 ₩ 7,129,000 Unprintable PDF by E-mail (Single User License)
US $ 6,950 ₩ 8,327,000 Printable PDF by E-mail (5-User License)
US $ 8,950 ₩ 10,723,000 Printable PDF by E-mail (Enterprise License)


육종 치료제 시장 규모, 점유율, 동향 분석 : 치료 유형별(화학요법, 표적요법), 주요 시장별(미국, 영국, 독일, 스페인, 이탈리아, 프랑스, 일본), 부문 예측(2018-2023년) Sarcoma Drugs Market Size, Share & Trends Analysis Report By Treatment Type (Chemotherapy, Targeted Therapy), By Major Markets (U.S., U.K., Germany, Spain, Italy, France, Japan), And Segment Forecasts, 2018 - 2023
발행일 : 2018년 07월 페이지 정보 : 영문 93 Pages

세계의 육종 치료제 시장 규모는 2023년까지 12억 달러에 이를 것으로 예측됩니다. 신제품 출시와 새로운 치료법 보급, 표적 인구 증가가 시장 성장을 촉진하고 있습니다.

세계의 육종(Sarcoma) 치료제 시장을 조사했으며, 시장 현황과 2023년까지 성장 예측, 치료 유형별·주요 시장별 동향, 시장 진출기업 개요 등을 정리하여 전해드립니다.

제1장 조사 방법

제2장 주요 요약

제3장 질환 개요와 역학

  • 질환 개요
    • 연부조직 육종
    • 골육종
    • 현재 7대 시장의 이환율과 발증률

제4장 시장 개요

  • 시장 개요
  • 치료별 시장
  • 시장 규모와 예측
  • 7대 시장의 시장 규모와 예측
  • 기업별 시장 점유율 분포
  • 시장 동향과 브랜드 전략
  • 특허 만료 분석
  • 성장 촉진요인과 저해요인
  • 인수합병(M&A), 거래 동향
  • 가격 설정과 상환 시나리오
  • SWOT 분석

제5장 파이프라인 인텔리전스

  • 파이프라인 환경
  • 주요 연구개발 동향
  • 파이프라인 환경
  • 파괴적 약제의 임상 프로파일
  • 세계 파이프라인 예측

제6장 기업 개요

  • Novartis
  • Pfizer
  • Eli Lilly
  • Eisai
  • Johnson & Johnson
  • Bayer

제7장 시장 전망

LSH 18.09.05

List of Tables

  • TABLE 1 Sarcoma - Classification
  • TABLE 2 Soft-Tissue Sarcoma - Staging and Five-Year Survival Rate
  • TABLE 3 Bone Sarcoma - Staging and Five-Year Survival Rate
  • TABLE 4 First-line Chemotherapy for Sarcoma (Generics)
  • TABLE 5 Marketed Drugs for Sarcoma
  • TABLE 6 Sales by Treatment Type, in $ Million, 2017 - 2023
  • TABLE 7 Sales Performance by Country, in $ Million, 2017 - 2023
  • TABLE 8 U.S., Sales by Treatment Type (2017 - 2023)
  • TABLE 9 U.K., Sales by Treatment Type (2017 - 2023)
  • TABLE 10 Germany, Sales by Treatment Type (2017 - 2023)
  • TABLE 11 France, Sales by Treatment Type (2017 - 2023)
  • TABLE 12 Italy, Sales by Treatment Type (2017 - 2023)
  • TABLE 13 Spain, Sales by Treatment Type (2017 - 2023)
  • TABLE 14 Japan, Sales by Treatment Type (2017 - 2023)
  • TABLE 15 Patent Expiry Analysis
  • TABLE 16 R&D Pipeline Overview - Leading Drugs
  • TABLE 17 Late Stage Pipeline Analysis
  • TABLE 18 BLU-285 (avapritinib)
  • TABLE 19 INNO-206 (Aldoxorubicin)
  • TABLE 20 TRC105 (carotuximab)
  • TABLE 21 Pipeline Forecast
  • TABLE 22 Novartis Product Forecast Sales (2017 - 2023)
  • TABLE 23 Pfizer Product Forecast Sales (2017 - 2023)
  • TABLE 24 Eli Lilly Product Forecast Sales (2017 - 2023)
  • TABLE 25 Eisai - Product Forecast Sales (2017 - 2023)
  • TABLE 26 Johnson & Johnson Product Forecast Sales (2017 - 2023)
  • TABLE 27 Bayer Product Forecast Sales (2017 - 2023)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information Procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modelling for market share assessment
  • FIG. 7 Sarcoma Major Subtypes
  • FIG. 8 U.S. - Soft Tissue Sarcoma Incidence and Mortality Trends
  • FIG. 9 U.S. - Bone Sarcoma Incidence and Mortality Trends
  • FIG. 10 U.K.- STS Incidence Rates per 100,000 Population, by Sex
  • FIG. 11 U.K.-Bone Sarcoma Incidence Rates per 100,000 Population, by Sex
  • FIG. 12 Germany- Sarcoma Incidence and Mortality Trends
  • FIG. 13 Germany- Age-Standardized Incidence Rate per 100,000 people
  • FIG. 14 France - STS Age-Standardized Incidence Rate per 100,000 people
  • FIG. 15 Japan - Sarcoma Incidence Trends
  • FIG. 16 Treatment Type, Market Share Distribution, 2017 and 2023
  • FIG. 17 Regional Market Size, 2017 & 2023
  • FIG. 18 Market Shares Distribution, by Company (2017 & 2023)
  • FIG. 19 Sarcoma Sector SWOT
  • FIG. 20 Sarcoma R&D Pipeline - Drugs in Development
  • FIG. 21 Sarcoma R&D Pipeline, by Treatment Type
  • FIG. 22 Immunotherapy Types In Development for Sarcoma Treatment
  • FIG. 23 Novartis Sarcoma Sales Forecast
  • FIG. 24 Novartis SWOT Analysis
  • FIG. 25 Pfizer Sarcoma Sales Forecast
  • FIG. 26 Pfizer SWOT Analysis
  • FIG. 27 Eli Lilly Sarcoma Sales Forecast
  • FIG. 28 Eli Lilly SWOT Analysis
  • FIG. 29 Eisai Sarcoma Sales Forecast
  • FIG. 30 Eisai SWOT Analysis
  • FIG. 31 Johnson & Johnson Sarcoma Sales Forecast
  • FIG. 32 Johnson & Johnson SWOT Analysis
  • FIG. 33 Bayer Sarcoma Sales Forecast
  • FIG. 34 Bayer SWOT Analysis

The global sarcoma drugs market size is expected to be valued at USD 1.2 billion by 2023, as per a new report by Grand View Research, Inc., progressing at a CAGR of 8.5% during the forecast period. The growth of the market is largely driven by factors such as new product launches, increasing adoption of novel therapeutics, and growing target population.

Sarcomas account for less than 1.0% of all adult cancers. Though sarcomas represent a heterogeneous group of over 50 different histological subtypes, the two major subtypes are soft tissue sarcomas (STS) and bone sarcoma. Approximately, 12,000 patients in the U.S. and 28,000 patients in Europe are diagnosed with STS every year.

For over 40 years, mainstay of localized sarcoma treatment included surgical resection followed by neoadjuvant or adjuvant radiation or chemotherapy. However, even after complete surgical resection, about 50.0% of patients with intermediate or high grade sarcoma develop metastatic disease. Introduction of targeted therapy has revolutionized treatment paradigm for sarcoma. Targeted therapies and pipeline breakthroughs will continue to play a pivotal role in the growth of the market throughout the forecast period.

Further key findings from the report suggest:

EU5 will remain the second largest market with more than 30% share by 2023. The growth of the segment can be attributed to rising incidence of STS, uptake of targeted therapies, and increasing R&D activities

  • Eli Lilly's Lartuvo has displaced standard doxorubicin therapy as front-line STS treatment and is anticipated to maintain its prominence in the market over the forecast period
  • Strong unmet needs within the market present a key opportunity to develop breakthrough first-in-class therapies. Out of 45 drugs in the pipeline for sarcoma, seven are in Phase III, 22 in Phase II, two in Phase I/II trials, and the remaining in Phase I and Pre-clinical trials
  • The potential role for use of immuno-oncology agents in sarcomas is currently under evaluation in Phase I/II clinical trials
  • Companies with late-stage pipeline products for sarcoma are likely to enter the market by 2019 and would capture more than 10.0% of the sarcoma market share in 2023
  • Drugs with novel targets in early-phase development include Novartis's Afinitor (mTOR inhibitor), Tesaro's Zejula (PARP inhibitor), Amgen's Imlygic (gene therapy), and Pfizer's Crizotinib (ALK and MET tyrosine kinases inhibitor)
  • Role of VEGF inhibitors and mTOR inhibitors is under evaluation in multiple early phase trials. However, no statistically significant data has been reported till date

Table of Contents

Chapter 1 Research Methodology

  • 1.1. Information procurement
  • 1.2. Information or Data Analysis
    • 1.2.1. Market Formulation & Validation

Chapter 2 Executive Summary

Chapter 3 Disease Primer and Epidemiology

  • 3.1 Disease Primer
    • 3.1.1 Soft Tissue Sarcoma (STS)
    • 3.1.2 Bone Sarcoma
    • 3.1.3 Current Prevalence Rate and Incidence Rate for Seven Major Markets (U.S.,Japan,EU5)

Chapter 4 Global Sarcoma Drugs Market Overview

  • 4.1 Sarcoma Drugs Market Overview
    • 4.1.1 Tyrosine kinase inhibitors (c-KIT, PDGFR, and VEGF inhibitors)
    • 4.1.2 Cell Cycle Inhibitors
    • 4.1.3 mTOR inhibitors
  • 4.2 Market, by Treatment Type
  • 4.3 Market Size and Forecast (2017 - 2023)
  • 4.4 Market Size and Forecast, by Seven Major Markets (2017 - 2023)
    • 4.4.1 U.S. Sales by Treatment Type (2017 - 2023)
    • 4.4.2 U.K. Sales by Treatment Type (2017 - 2023)
    • 4.4.3 Germany Sales by Treatment Type (2017 - 2023)
    • 4.4.4 France Sales by Treatment Type (2017 - 2023)
    • 4.4.5 Italy Sales by Treatment Type (2017 - 2023)
    • 4.4.6 Spain Sales by Treatment Type (2017 - 2023)
    • 4.4.7 Japan Sales by Treatment Type (2017 - 2023)
  • 4.5 Market Share Distribution, by Company (2017 - 2023)
  • 4.6 Market Dynamics and Brand Strategies
  • 4.7 Patent Expiry Analysis
  • 4.8 Sarcoma Drugs Market: Drivers and Restraints
    • 4.8.1 Market Drivers
    • 4.8.2 Market Restraints
  • 4.9 M&A, Deal Landscape (2013-2018 YTD)
    • 4.9.1 Mergers & Acquisitions
    • 4.9.2 Deals Landscape
  • 4.10 Pricing and Reimbursement Scenario
  • 4.11 Sarcoma Sector SWOT

Chapter 5 Sarcoma Drugs Market: Pipeline Intelligence

  • 5.1 Pipeline Landscape
    • 5.1.1 Leading Drugs in Development
  • 5.2 Key R&D Trends
    • 5.2.1 Chemotherapy
    • 5.2.2 Targeted Therapy
    • 5.2.3 Immunotherapy
      • 5.2.3.1 Immuno-oncology agents
      • 5.2.3.2 Cancer Vaccines
      • 5.2.3.3 Gene Therapy
  • 5.3 Pipeline Landscape
    • 5.3.1 Late Stage Pipeline Drugs
  • 5.4 Clinical Profiles of Disruptive Drugs
  • 5.5 Global Pipeline Forecast

Chapter 6 Company Profiles

  • 6.1 Novartis
    • 6.1.1 Company Overview
    • 6.1.2 Product Portfolio
    • 6.1.3 Product Forecast Sales through 2023
    • 6.1.4 Strategic Initiatives
      • 6.1.4.1 Key Company News Flow
    • 6.1.5 Pipeline Analysis and Overview
    • 6.1.6 SWOT
  • 6.2 Pfizer
    • 6.2.1 Company Overview
    • 6.2.2 Product Portfolio
    • 6.2.3 Product Forecast Sales through 2023
    • 6.2.4 Strategic Initiatives
      • 6.2.4.1 Key Company News Flow
    • 6.2.5 Pipeline Analysis and Overview
    • 6.2.6 SWOT
  • 6.3 Eli Lilly
    • 6.3.1 Company Overview
    • 6.3.2 Current Product Portfolio
    • 6.3.3 Product Forecast Sales through 2023
    • 6.3.4 Strategic Initiatives
      • 6.3.4.1 Key Company News Flow
      • 6.3.4.2 Catalysts & Events Calendar
    • 6.3.5 Pipeline Analysis and Overview
    • 6.3.6 SWOT
  • 6.4 Eisai
    • 6.4.1 Company Overview
    • 6.4.2 Product Portfolio
    • 6.4.3 Product Forecast Sales through 2023
    • 6.4.4 Strategic Initiatives
      • 6.4.4.1 Key Company News Flow
    • 6.4.5 Pipeline Analysis and Overview
    • 6.4.6 SWOT
  • 6.5 Johnson & Johnson
    • 6.5.1 Company Overview
    • 6.5.2 Product Portfolio
    • 6.5.3 Product Forecast Sales through 2023
    • 6.5.4 Strategic Initiatives
      • 6.5.4.1 Key Company News Flow
    • 6.5.5 Pipeline Analysis and Overview
    • 6.5.6 SWOT
  • 6.6 Bayer
    • 6.6.1 Company Overview
    • 6.6.2 Product Portfolio
    • 6.6.3 Product Forecast Sales through 2023
    • 6.6.4 Strategic Initiatives
      • 6.6.4.1 Key Company News Flow
    • 6.6.5 Pipeline Analysis and Overview
    • 6.6.6 SWOT

Chapter 7 Market Outlook

  • 7.1. What the Future Holds
  • 7.2. The Winners and Losers
    • 7.2.1. Winners
    • 7.2.2. Losers
  • 7.3. Emerging Companies/New Technology Platforms
  • 7.4. The Road Ahead
Back to Top
전화 문의
F A Q